Binod Dhakal, Medical College of Wisconsin, Milwaukee, US, presents the PROMMIS study which prospectively measured the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma (NDMM). This interview was conducted during ASCO 2019, held in Chicago, US. Binod Dhakal discusses how MMprofiler (92 gene) was utilized to classify patients within risk categories and then assist in determining treatment. For NDMM, the MMprofiler was helpful to confirm treatment and the trial is continuing to enroll, with further data expected at EHA 2019.
The European School of Haematology (ESH) is a not for profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology